Skip to content

A Randomized Controlled Clinical Study on the Application of the Third Space in the Operation of Gastric Submucosal Tumor

Comparison of Laparoscopic and Endoscopic Cooperative Surgery and Robotic and Endoscopic Cooperative Surgery in the Operation of Gastric Submucosal Tumor

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03612830
Acronym
RECSINSMTs
Enrollment
80
Registered
2018-08-02
Start date
2018-04-11
Completion date
2020-12-30
Last updated
2018-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Submucosal Tumors

Keywords

The Third Space

Brief summary

Gastric submucosal tumors (SMTs) are rare findings during routine upper endoscopy; the incidence of these lesions may be as high as 0.4%.SMTs display a wide spectrum,ranging from benign to highly malignant, with gastrointestinal stromal tumors (GISTs) being the most common type.SMTs is a gastrointestinal tumor,surgical operation is still the main method of gastric tumor treatment.The common surgical methods for resection of SMTs include laparotomy and laparoscopic surgery.In recent years, the Da Vinci robot assisted gastric resection has become a new way to treat gastric cancer. Compared with the traditional laparoscopy and laparotomy, the operation of the robot is more precise and flexible, with obvious advantages of minimally invasive and good application value and prospect.In recent years, some scholars have put forward the concept of the third space.The concept of the third space was initiatively proposed at the same time when new endoscopic surgery approach via natural orifice transluminal was put forward(NOTES). To be specific, with respect to the first space(lumen) and second space(peritoneal cavity),the third space refers to the intramural space.The aim of the study is to compare value (outcomes/costs) of surgery in patients with SMTs by 2 approaches:Laparoscopic and Endoscopic cooperative surgery(LECS),Robotic and Endoscopic cooperative surgery(RECS).First of all, the investigators will collect 80 cases of SMTs patients, randomly assigned for the LECS and RECS groups. Secondly, to analyzing the demographic data,basic treatment and follow-up data, including the operation time, blood loss, the number of cut edge positive, the distances of cut edge away from the tumor edge, average such confinement, the meal time, cost of treatment, tumor recurrence rate, the presence of residual stomach, upset stomach and frequency,complications and other indicators.

Interventions

PROCEDURELaparoscopy endoscopy cooperated surgery

LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy

PROCEDUREDan Vinchi robot endoscopy cooperated surgery

RECS resects the tumor completely by Dan Vinchi Robot with the help of the precise positioning and guidance of endoscopy

Sponsors

Air Force Military Medical University, China
CollaboratorOTHER
First Affiliated Hospital Xi'an Jiaotong University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Intervention model description

Laparoscopic and Endoscopic cooperative sugery,Robotic and Endoscopic cooperative sugery

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients without contraindications gastroscope,surgery and anesthesia; * Gastroscope found submucosal lesions, qualitative hard;Endoscopic ultrasonography (EUS) confirmed the lesions come from the muscularis propria; * Tumors diameter \> 2 cm;Or tumors had \< 2 cm, but the position is located in the stomach wall, after nearly cardia and it is a difficult position for gastroscope ; * Tumors diameter \< 5 cm, the tumors had complete, no broken feed and bleeding; * Not found the tumor metastasis; * There is no history of abdominal surgery, no severe abdominal cavity adhesion * Normal coagulation function; * There is no history of anticoagulant drugs, or who take aspirin, salvia miltiorrhiza, etc., should stop taking drugs for more than one week; * Patients and their families volunteered choice the surgical procedure and signed informed consent.

Exclusion criteria

* Patients with preoperative assessment of distant metastasis; * Patients with preoperative radiation and chemotherapy or hormone therapy; * Patients with acute obstruction, bleeding or perforation of the emergency surgery; * Patients with a history of abdominal trauma or abdominal surgery; * Patients with contraindications gastroscope,surgery and anesthesia.

Design outcomes

Primary

MeasureTime frameDescription
operation time1 hours to 6 hours through the surgery completionrecord in minutes,from the beginning of anesthesia to the end

Secondary

MeasureTime frameDescription
success ratefrom two days to two weeks after surgeryto ensure the integrity of the tumor and obtain the negative surgical margin
time in bedfrom two days to two weeks after surgerythe time in bed to the postoperative patient
time to take foodfrom two days to two weeks after surgerythe time to eat to the postoperative patient
blood loss1 hours to 6 hours through the surgery completionfrom the surgical record sheet
tumor recurrence ratefrom one month to 2 years after surgeryperiodic review the CT or MRI or endoscope
hospitalization expenses1 monthtotal hospitalization expenses
postoperative complication ratefrom two weeks to one year after surgeryincluding anastomotic stoma fistula,anastomotic stenosis,abdominal infection,postoperative bleeding

Countries

China

Contacts

Primary ContactJun Jun She, M.D; PhD
sjuns@sina.com008618991232713

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026